Smith & Nephew PLC (LSE:SN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter.
The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year.
Orthopaedics grew 3.2% on an underlying basis, with stronger performance in US hip and knee implants and solid growth in other reconstruction and trauma treatments.
The sports medicine and ENT division posted 2.4% underlying growth, with gains in joint repair and arthroscopic technologies offset by China-related pressures.
Advanced Wound Management grew 3.8% driven by foams and negative pressure wound therapy products.
CEO Deepak Nath said: “We have delivered a good start to the year with the operational improvements delivered through the 12-Point Plan driving growth across our portfolio.”
The company maintained its full-year 2025 guidance for around 5% underlying revenue growth and a trading profit margin between 19% and 20%. It said an expected $15–20 million impact from tariffs is already accounted for in its outlook.